IVD Reagent Manufacturer: Complaint Trend, Supplier Change and a Weak CAPA
You are the quality lead at an IVD reagent manufacturer with 120 employees and an ISO 13485 certificate covering design, production, and distribution. Over six months, seven complaints from one hospital network report elevated imprecision at low analyte levels. A CAPA was opened four months ago; the root cause was recorded as 'operator error at the customer site', and the corrective action was customer retraining. No effectiveness check has been performed. Production records show the affected reagent lots used an incoming antibody lot from a supplier that changed its purification process without notifying you. Your nonconforming product procedure permits 'use-as-is' release with R&D sign-off, and two affected lots were released that way. The complaints were not reported to the competent authority because the company judged them 'not serious'. Management review minutes do not mention CAPA or complaint trends.
1. Evaluate the CAPA. Was the root cause adequate, and what should happen next?
Read the worked answer
The CAPA is not adequate. 'Operator error at the customer site' is a conclusion that does not explain why seven complaints arose in one hospital network while other customers did not report the same problem. Under 8.5.2, corrective action must address the root cause and verify effectiveness. The investigation should examine reagent lot performance, incoming antibody variability, assay calibration, sample handling instructions and the supplier's purification change. The absence of an effectiveness check is a clear gap; retraining customers is not evidence that the reagent performs as intended. Reopen or replace the CAPA, define a fault tree, test retained samples from affected and unaffected lots, review trend data and involve the supplier. If the supplier change altered antibody characteristics, the root cause may be an unapproved supplier process change. Set measurable effectiveness criteria, such as zero recurrence over a defined period and acceptable precision data. Link the CAPA to risk management and to any regulatory reporting decision.
2. How should the supplier change and the two 'use-as-is' lots be handled?
Read the worked answer
The supplier's purification change is a change to purchased product that can affect reagent performance. Under 7.4.2, purchasing information should require notification of process changes; under 7.4.1, the supplier should be re-evaluated. Obtain the supplier's change description, comparability data and impact on antibody performance. Quarantine remaining material from that supplier lot and assess all affected finished lots. The 'use-as-is' release of two lots needs scrutiny: 8.3 requires justification, approval by authorized personnel, and evidence that the product still meets requirements. An R&D sign-off alone is weak if precision at low analyte levels is affected. Review the nonconforming product procedure and require risk assessment, customer notification where applicable, and regulatory reporting evaluation. If the lots remain in the field, consider a field safety corrective action. Update supplier agreements to require change notification and revalidation before shipment.
3. What should be done about regulatory reporting and management review?
Read the worked answer
The company cannot rely on its own judgment that complaints are 'not serious' without a documented evaluation against the applicable regulatory criteria. Under 8.2.3, the organization must have a procedure for notification to regulatory authorities when required. Assess the seven complaints for reportability, considering the potential for erroneous IVD results and clinical impact. Document the decision and rationale even if reporting is not required. For management review under 5.6, complaint trends, CAPA status, regulatory actions and risk should be inputs. The absence of CAPA and complaint trends in the minutes is a nonconformity in practice because top management cannot review the suitability and effectiveness of the QMS without them. Add these inputs, review the supplier issue and the use-as-is releases, and record decisions and actions. Then verify that the revised CAPA and reporting process are effective.